Art

J-GLOBAL ID：201702228733286722   Reference number：17A1410153

Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy

ダクラタスビルおよびアスナプレビル併用療法で治療が失敗した患者におけるソホスブビル,レジパスビル,およびリバビリン追加による再治療

Author (22)： SUDA Goki (Hokkaido Univ., Hokkaido, JPN) ,  OGAWA Koji (Hokkaido Univ., Hokkaido, JPN) ,  YAMAMOTO Yoshiya (Hakodate City General Hospital, Hokkaido, JPN) ,  KATAGIRI Masaki (Sapporo Hokuyu Hospital, Hokkaido, JPN) ,  FURUYA Ken (Hokkaido Hospital, Hokkaido, JPN) ,  KUMAGAI Kenichi (Mori City National Health Insurance Hospital, Hokkaido, JPN) ,  KONNO Jun (Hakodate Central General Hospital, Hokkaido, JPN) ,  KIMURA Megumi (Hokkaido Univ., Hokkaido, JPN) ,  KAWAGISHI Naoki (Hokkaido Univ., Hokkaido, JPN) ,  OHARA Masatsugu (Hokkaido Univ., Hokkaido, JPN) ,  UMEMURA Machiko (Hokkaido Univ., Hokkaido, JPN) ,  ITO Jun (Hokkaido Univ., Hokkaido, JPN) ,  IZUMI Takaaki (Hokkaido Univ., Hokkaido, JPN) ,  NAKAI Masato (Hokkaido Univ., Hokkaido, JPN) ,  SHO Takuya (Hokkaido Univ., Hokkaido, JPN) ,  NATSUIZAKA Mitsuteru (Hokkaido Univ., Hokkaido, JPN) ,  MORIKAWA Kenichi (Hokkaido Univ., Hokkaido, JPN) ,  TSUBOTA Akihito (Jikei Univ. School of Medicine, Tokyo, JPN) ,  SHIMADA Noritomo (Ootakanomori Hospital, Chiba, JPN) ,  IIO Etsuko (Nagoya City Univ. Graduate School of Medical Sci., Nagoya, JPN) ,  TANAKA Yasuhito (Nagoya City Univ. Graduate School of Medical Sci., Nagoya, JPN) ,  SAKAMOTO Naoya (Hokkaido Univ., Hokkaido, JPN)
Material： Journal of Gastroenterology  (J Gastroenterol)
Volume： 52  Issue： 10  Page： 1122-1129  Publication year： 2017 
JST Material Number： Z0748A  ISSN： 0944-1174  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： 前方視的検討 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1410153&from=J-GLOBAL&jstjournalNo=Z0748A") }}

JST classification (2)： Treatment for infectious diseases,parasitic diseases.  (GD01030D) ,  Drug therapy(=pharmacotherapy)for digestive system diseases  (GH05020G)

Substance index (6)： BMS-790052 ,  BMS-650032 ,  Sofosbuvir ,  Ledipasvir ,  Ribavirin ,  Simeprevir

Reference (27)：

• Suda G, Kudo M, Nagasaka A, et al. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol. 2016;1(7):733-40.
• Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645-53.
• Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083-91.
• Ito J, Suda G, Yamamoto Y, et al. Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. Hepatol Res. 2016;46(13):1294-303.
• Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58(4):655-62 Epub 2012 Nov 23.

Terms in the title (10)： ダクラタスビル ,  アスナプレビル ,  併用療法 ,  治療 ,  失敗 ,  患者 ,  ソホスブビル ,  レジパスビル ,  リバビリン ,  再治療